Entrada Therapeutics Q3 net loss narrows as expenses fall

Overview

• US biopharma developer's Q3 collaboration revenue declined yr/yr

• Net loss for Q3 narrowed from a year earlier

• Operating expenses fell, mainly due to lower preclinical and facility costs

Outlook

• Entrada expects ELEVATE-44-201 Cohort 1 data by year-end 2026

• Company on track to report ELEVATE-44-201 Cohort 2 data in Q1 2027

• Entrada expects ELEVATE-45-201 Cohort 2 data in H1 2027

Result Drivers

• LOWER PRECLINICAL COSTS - Co said R&D expenses fell mainly due to lower preclinical costs for Duchenne programs and lower facility-related costs

• DECLINE IN COLLABORATION REVENUE - Co attributed lower collaboration revenue to timing of partner activities

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Entrada Therapeutics, Inc. is $17.00, about 236% above its November 4 closing price of $5.06

Reuters Recommended Reads

• Nov 4 - Solid Biosciences Q3 net loss widens on higher R&D costs

• Nov 4 - Lyell Immunopharma Q3 net loss widens on higher R&D spending

• Nov 4 - Relay Therapeutics Q3 loss smaller than estimates; sees breast cancer trial enrollment complete mid-2027

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)